ModifiedCentenePolicy CP MP.113

Holter Monitors (ambulatory ECG up to 48 hours)

Medical necessity guidelines for ambulatory ECG Holter monitoring up to 48 hours for Centene-affiliated health plans, describing covered indications, coding references, and supporting clinical background for providers.

Policy Summary

PayerCentene

PolicyHolter Monitors (ambulatory ECG up to 48 hours)

Policy CodePolicy CP MP.113

Change TypeCriteria revised and addedoperational edits

Effective Date

Next Review Date

Key ActionSubmit CPT 93224-93227 with supporting diagnosis codes and documentation of a covered indication; use an FDA-approved Holter device.

SourceLink

POLICY UPDATE CHANGES

Criteria updated to specify an FDA-approved Holter monitor device and clarified age wording in adult and pediatric criteria.

Added criteria for baseline or periodic screening for those with adult congenital heart disease.

Removed prior statement that efficacy is not established for all other indications in pediatric criteria II.

24-48 hrsduration of Holter monitoring addressed

93224-93227CPT codes referenced

Adult & Pediatricpopulations covered

ICD-10 tablediagnosis codes supporting coverage

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Ambulatory ECG (Holter) Monitoring (up to 48 hours)

inv-01: Adult Covered Indications (24–48 hours)

Covered when ANY of the following adult indications are met:

Adult Holter indications: Evaluation of unexplained syncope, near-syncope, episodic dizziness, recurrent palpitations, episodic shortness of breath, or chest pain; evaluation of neurological events when transient atrial fibrillation or flutter is suspected; evaluation for cardiomyopathy (arrhythmogenic right ventricular cardiomyopathy [ARVC], hypertrophic cardiomyopathy [HCM], dilated cardiomyopathy), or a first-degree relative with ARVC or HCM; persistent symptoms despite treatment of an identified probable non-arrhythmic cause; possible or documented prolonged QT syndromes; screening for asymptomatic arrhythmia in members/enrollees with Brugada syndrome; assessment of efficacy of antiarrhythmic medication when baseline arrhythmia frequency is reproducible and sufficient for analysis; detection of proarrhythmic responses to antiarrhythmic therapy in high-risk patients; evaluation of suspected pacemaker or ICD component failure or malfunction when device interrogation is inconclusive; assessment of pacemaker or ICD function for frequent palpitations, syncope, or near-syncope and to assist programming; assessment of efficacy of adjunctive medications in members/enrollees receiving frequent ICD therapy; evaluation of recurrent chronic heart failure when arrhythmia is suspected; assessment of suspected variant angina; evaluation of possible arrhythmias post ablation procedures; baseline or periodic screening for adult congenital heart disease.device: FDA-approved; duration: up to 48 hours

Age: ≥ 18 years; Holter device must be FDA-approved.

inv-02: Pediatric Covered Indications (24–48 hours)

Covered when ANY of the following pediatric indications are met:

Pediatric Holter indications: Evaluation of syncope or near-syncope associated with exertion when cause is not established; evaluation of syncope, near-syncope, or dizziness in children with identified cardiac disease, previously documented arrhythmia, or pacemaker dependency; evaluation of unexplained syncope, near-syncope, or sustained palpitations when there is no overt clinical evidence of heart disease; evaluation of patients with cardiomyopathy (hypertrophic or dilated) or a first-degree relative with arrhythmogenic right ventricular cardiomyopathy; assessment of efficacy of medications for arrhythmia following initiation of treatment or during somatic growth; possible or documented prolonged QT syndromes; evaluation of asymptomatic congenital complete atrioventricular (AV) block (non-paced); evaluation of palpitations after surgery for congenital heart disease with significant residual hemodynamic abnormalities; evaluation of cardiac rhythm after transient AV block associated with heart surgery or catheter ablation; evaluation of rate-responsive or physiologic pacing function in symptomatic patients.device: FDA-approved; duration: up to 48 hours

Age: < 18 years; Holter device must be FDA-approved.

The policy text was revised to remove a prior statement in the pediatric section that characterized efficacy as "not established" for other indications. This operational change does not add new exclusions but clarifies that the previous non‑efficacy wording in pediatric Criteria II has been deleted from the document.

Coverage determinations under this clinical policy are subject to the terms, conditions, exclusions and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract of insurance) and to applicable state and federal requirements and Health Plan administrative policies and procedures.

The provided document excerpt does not contain an explicit "not medically necessary" statement. Earlier text revisions removed wording about efficacy not being established for certain pediatric indications; therefore readers should rely on the listed covered indications and the plan’s benefit terms rather than expecting a separate formal "not medically necessary" section in this excerpt.

Coding and Diagnosis References

Covered CPT CodesCPTCovered

93224	External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional.
93225	External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; recording (includes connection, recording, and disconnection).
93226	External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; scanning analysis with report.
93227	External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional.

ICD-10 Diagnosis Codes that Support CoverageICD-10

G45.9	Transient cerebral ischemic attack, unspecified
I48.0-I48.92	Atrial fibrillation and flutter (range noted in policy)
I50.1-I50.9	Heart failure (range noted in policy)
R55	Syncope and collapse
R42	Dizziness and giddiness
Z95.0	Presence of cardiac pacemaker
Z95.810	Presence of automatic (implantable) cardiac defibrillator

What Providers Must Do

Prior Authorization

Prior Authorization Required

Prior authorization is required for Holter monitoring (24–48 hours) when the service is subject to the Health Plan's prior authorization program. Submit documentation that the request meets covered indications and include supporting CPT and ICD-10 codes and clinical rationale to justify medical necessity.

Include relevant CPT codes (e.g., 93224–93227) and supporting ICD-10 diagnosis codes on the prior authorization request and claim.
Document the covered clinical indication (symptoms, frequency, prior evaluations) in the medical record and attach to the PA submission when required.

Billing Rule

Coding and Diagnosis Documentation

Claims and clinical documentation must be supported with appropriate CPT and ICD-10 codes. Use CPT codes 93224, 93225, 93226, and 93227 as applicable for external continuous ECG recording up to 48 hours. Include the ICD-10 diagnosis code(s) that best support the medical necessity for ambulatory ECG monitoring.

Definitions and Clinical Policy Terms

inv-17: Holter monitoring (ambulatory ECG) — definition

DefinitionContinuous external electrocardiographic recording performed over a 24–48 hour period to detect cardiac arrhythmias, correlate patient‑reported symptoms with ECG changes, and assess therapy or device performance.

Primary purposesDetect arrhythmias, correlate symptoms (palpitations, syncope/near‑syncope, dizziness, chest pain, shortness of breath) with ECG findings, and assess efficacy of antiarrhythmic medications or function of pacemakers/ICDs.

Typical use caseMost practical initial ambulatory monitoring approach for patients with daily or near‑daily unexplained symptoms and for assessing treatment efficacy.

Monitoring featuresNoninvasive continuous rhythm recording with patient‑activated event marker to annotate symptoms for later correlation with recorded data.

Duration referenced in policyUp to 48 hours (continuous recording for 24 to 48 hours).

Clinical Background

Ambulatory electrocardiographic (Holter) monitoring is a noninvasive method of continuously recording cardiac electrical activity over a typical duration of 24 to 48 hours to detect arrhythmias and to correlate symptoms such as palpitations, syncope or near‑syncope, dizziness, chest pain, or shortness of breath with ECG findings.

Holter monitoring is commonly used to evaluate unexplained episodic symptoms that occur daily or near‑daily and to assess the effectiveness of antiarrhythmic therapy or device function when baseline arrhythmia frequency is sufficient for analysis.

Because it provides continuous rhythm recording over the monitoring period, Holter monitoring is especially useful for short‑term symptom correlation and for evaluating pacemaker or ICD performance when device interrogation alone is inconclusive.

Policy Revision History and Material Changes

09/24operational

Removed prior pediatric statement that efficacy was not established for all other indications (non‑material administrative removal).

04/23material_added

Added new ICD‑10 codes to the policy and clarified criteria to specify use of an FDA‑approved Holter monitor device and updated adult criteria to add baseline or periodic screening for adult congenital heart disease.

09/23material_revised